INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Increased survival of patients with cystic fibrosis has focused attention on quality of life, alongside longevity1

Adults with CF have complex infections2– at least 170 different bacteria have been identified to comprise the microbiome of an adult with CF.2

As they get older, the respiratory microbiome of a person with CF changes.3,4

REPORTED LUNG INFECTIONS IN UK CF PATIENTS IN 20175

Adapted from Cystic Fibrosis Registry, 2017 Annual Data Report5

Pseudomonas aeruginosa is a common chronic infection, affecting up to 80% of adults with CF.4,6,7

Quinsair® (levofloxacin hemihydrate) is the first inhaled quinolone for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.8,9


1. Royce FH and Carl JC, Curr Opin Pediatr. 2011;23(5)535-40.
2. Price KE, et al. Microbiome. 2013;1-27.
3. Filkins L, et al. Plos Pathog. 2015;11(12):1-8.
4. Coburn B,et al. Sci Rep. 2015;5:10241. Doi:10.1038/prep10241.
5. UK Cystic Fibrosis Registry. Annual Data Report 2017. Cystic Fibrosis Trust.
6. LiPuma J. J Clin Micro Rev. 2010;23:299-23.
7. Smyth AR, et al. J Cyst Fibros. 2014;13:523-42.
8. Quinsair. European Medicines Agency. Assessment Report 2015. EMA/CHMP/676680/2015;1-106
9. Quinsair® Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/32009. Accessed September 2018.